Funding for this research was provided by:
Merck Sharp & Dohme Corp
Received: 11 June 2021
Accepted: 28 January 2022
First Online: 19 February 2022
: This research is not considered human subject research as it does not involve interactions with – or interventions among – participants, and only de-identified data was available. All database records are statistically de-identified and certified to be fully compliant with US patient confidentiality requirements set forth in the Health Insurance Portability and Accountability Act of 1996. Because this study used only de-identified patient records and did not involve the collection, use, or transmittal of individually identifiable data, this study was exempted from Institutional Review Board approval. Per The U.S. Department of Health and Human Services, Office of Human Research Protections regulations, the analysis of de-identified data does not constitute human subjects research as defined at 45 CRF 46.102 and as such it does not require IRB review [CitationRef removed].
: Not applicable.
: RK and FC are employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA who may own stock and/or hold stock options in Merck & Co., Inc.,Kenilworth, NJ, USA. BL and ET are employed by IBM Watson Health which received funding from Merck to conduct this study.